JP6957355B2 - 血清型交差反応性デング熱中和抗体及びその使用 - Google Patents

血清型交差反応性デング熱中和抗体及びその使用 Download PDF

Info

Publication number
JP6957355B2
JP6957355B2 JP2017549051A JP2017549051A JP6957355B2 JP 6957355 B2 JP6957355 B2 JP 6957355B2 JP 2017549051 A JP2017549051 A JP 2017549051A JP 2017549051 A JP2017549051 A JP 2017549051A JP 6957355 B2 JP6957355 B2 JP 6957355B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
denv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514193A (ja
JP2018514193A5 (enExample
Inventor
ワン、チェン−アイ
フィンク、カジャ
マカリー、ポール
チュスト、ローランド
シュ、メイフイ
Original Assignee
エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ
ナショナル ユニバーシティ オブ シンガポール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ, ナショナル ユニバーシティ オブ シンガポール filed Critical エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ
Publication of JP2018514193A publication Critical patent/JP2018514193A/ja
Publication of JP2018514193A5 publication Critical patent/JP2018514193A5/ja
Application granted granted Critical
Publication of JP6957355B2 publication Critical patent/JP6957355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017549051A 2015-03-17 2016-03-17 血清型交差反応性デング熱中和抗体及びその使用 Active JP6957355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201502068V 2015-03-17
SG10201502068V 2015-03-17
PCT/SG2016/050124 WO2016148653A1 (en) 2015-03-17 2016-03-17 A serotype cross-reactive, dengue neutralizing antibody and uses thereof

Publications (3)

Publication Number Publication Date
JP2018514193A JP2018514193A (ja) 2018-06-07
JP2018514193A5 JP2018514193A5 (enExample) 2019-04-04
JP6957355B2 true JP6957355B2 (ja) 2021-11-02

Family

ID=56920185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549051A Active JP6957355B2 (ja) 2015-03-17 2016-03-17 血清型交差反応性デング熱中和抗体及びその使用

Country Status (6)

Country Link
US (1) US10316078B2 (enExample)
EP (1) EP3271390B1 (enExample)
JP (1) JP6957355B2 (enExample)
CN (1) CN107531779B (enExample)
SG (1) SG11201707592TA (enExample)
WO (1) WO2016148653A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
IL277375B2 (en) * 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
TWI737918B (zh) * 2018-06-12 2021-09-01 國防醫學院 抗登革病毒抗體及其應用
CN109929033B (zh) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种特异性结合四种血清型登革病毒的人源抗体
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022163845A1 (ja) * 2021-01-31 2022-08-04 株式会社バランス・イースト 検査システム、検査方法、プログラム、およびコンピュータが読み取り可能な記憶媒体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753418B2 (en) 2000-10-05 2004-06-22 Case Western Reserve University Suppressors of human breast cancer cell growth
US8470976B2 (en) 2006-06-17 2013-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting macromolecules into the nucleus
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
JP5814790B2 (ja) * 2008-10-13 2015-11-17 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ デングウイルス中和抗体およびその使用
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
US20140349321A1 (en) * 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
AU2015217572B2 (en) * 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof

Also Published As

Publication number Publication date
EP3271390A4 (en) 2018-08-08
JP2018514193A (ja) 2018-06-07
EP3271390B1 (en) 2023-09-27
US20180072798A1 (en) 2018-03-15
US10316078B2 (en) 2019-06-11
SG11201707592TA (en) 2017-10-30
EP3271390A1 (en) 2018-01-24
CN107531779A (zh) 2018-01-02
WO2016148653A1 (en) 2016-09-22
CN107531779B (zh) 2021-04-13

Similar Documents

Publication Publication Date Title
JP6957355B2 (ja) 血清型交差反応性デング熱中和抗体及びその使用
US11912757B2 (en) Antibodies specifically binding to Zika virus epitopes and uses thereof
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
AU2011341744B2 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof
US20170298119A1 (en) Antibody molecules to zika virus and uses thereof
CA2963470A1 (en) Antibodies that bind ebola glycoprotein and uses thereof
CA3070780A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
US9738704B2 (en) Binding molecules against Chikungunya virus and uses thereof
EP3220947B1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
JP2022507836A (ja) 新規の抗ジカウイルス抗体及びその使用
US20230065377A1 (en) Human antibodies to alphaviruses
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
EP2374816B1 (en) Binding molecules against Chikungunya virus and uses thereof
JP2011072248A (ja) 狂犬病ウイルスに対するヒト抗体ならびにその組成物
WO2024053719A1 (ja) コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
US12037384B2 (en) Human monoclonal antibodies against yellow fever virus and uses therefor
US20240287160A1 (en) Antibody cocktail for treatment of ebolavirus infections
EP4349860A1 (en) Anti-sars-cov-2 antibodies
CN107286237A (zh) 一种抗丙型肝炎病毒抗体的获取以及应用
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
WO2025024431A1 (en) Broadly reactive antibodies to influenza b viruses
HK40025147B (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211006

R150 Certificate of patent or registration of utility model

Ref document number: 6957355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250